ATG-125
/ Antengene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 15, 2026
ATG-125 (B7-H3 × PD-L1 bispecific ADC)
(PRNewswire)
- "Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027."
IND • Preclinical • Oncology
1 to 1
Of
1
Go to page
1